Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of NBTXR3 activated by radiotherapy with or without cetuximab in platinum-ineligible elderly patients with locally advanced head and neck squamous cell carcinoma
2024-520386-31-00Phase 3Authorised
- Sponsor
- Johnson & Johnson
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing JNJ-90301900 + radiotherapy with JNJ-90301900 + radiotherapy + Erbitux (2 arms). Primary endpoint: Progression-free survival by independent central review. Planned start Sep 2025; status: authorised.
02
Drugs
NBTXR3cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-520386-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520386-31-00.